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Sunitinib malate (Sutent) is a small molecule ATP site-directed
competitive inhibitor. It inhibits multiple processes necessary
for tumour growth, including tumour cell proliferation and angi-
ogenesis, through its action on multiple receptor tyrosine
kinases.1
The initial development strategy for this anticancer agent was
to pursue approval for treating gastrointestinal stromal tumour
(GIST) and renal cell carcinoma (RCC) in parallel based on the sci-
entific rationale that GIST progression is characterised by KIT or
platelet-derived growth factor receptor (PDGFR) mutations and
that RCC is highly vascular and expresses vascular endothelial
growth factor receptor (VEGFR) as well as PDGFR. Preliminary effi-
cacy data on sunitinib fromphase I studies demonstrated that sun-
itinib had activity across tumour types, including GIST and RCC.
For RCC, the manufacturer’s initial strategy was to seek accel-
erated approval in United States based on two phase II studies in
cytokine-refractory patients using a primary endpoint of objec-
tive response rate. As shown in Table 1, the resulting response
rates were much higher than historical data for any other treat-
ment. A subsequent phase III study in treatment-naı¨ve patients
would be the basis for full approval in the United States, the Euro-
pean Union, and the rest of the world. The primary endpoint
would be progression-free survival (PFS) as a means of demon-
strating clinical benefit.
Scientific advice was sought about the possibility of registering
sunitinib in the European Union based on the phase II RCC stud-
ies. The feedback indicated that response-rate studies from two
phase II studies would be unlikely to provide sufficient evidence
for registration. Nevertheless, the company decided to seek
approval in the European Union because of the unmet need for
RCC patients and the compelling and consistent study results.
In addition, interim data from a randomised Phase III study com-
paring sunitinib and interferon-a in treatment-naı¨ve RCC patients
were expected to be available during the review period. The mar-
keting authorisation application (MAA) would also include ran-
domised GIST data showing safety in 202 additional patients
and efficacy in a second tumour type. Additionally, the company
could withdraw the RCC indication from the MAA if members of
the Committee for Medicinal Products for Human Use (CHMP)
objected. Ultimately, sunitinib received an Orphan Drug
Designation.
In its assessment report, the CHMP requested better justifica-
tion of clinical benefit from the phase II RCC data. Members of the
Scientific Advisory Group Oncology met in March 2006 and con-
cluded that the high response rate was likely to translate into a
clinically relevant effect on PFS and overall survival in RCC
patients. The supporting data were deemed to be of high quality
with radiologic confirmation of progressive disease on cytokine
therapy at recruitment and responses to sunitinib on study. The
group considered drug toxicity to be manageble. Additionally,
the interim analysis of the phase III study showed an ORR of
26% for sunitinib and 7% for interferon-a. The conclusion was
that the benefit–risk ratio was positive.
Nevertheless, several CHMP members thought the data were
inadequate for a normal marketing authorisation. Therefore, con-
ditional approval was granted in April 2006 with a specific obliga-
tion for subsequent normal approval to submit PFS data from the
phase III randomised study in treatment-naı¨ve RCC patients. The
specific obligation applied to both RCC and GIST because they
were included in the same MAA.
The interim results of the phase III study showed that PFS was
significantly longer for patients treated with sunitinib than with
interferon-a. Pfizer submitted these data and requested acceler-
ated review (60 days instead of 90). CHMP adopted a positive opin-
ion for a new indication for advanced and/or metastatic RCC. A
normal marketing authorisation was granted for both indications
6 months after conditional authorisation.
RCC patients benefited by having earlier access to an effective
new therapy than would have been the case if phase III data were
required. This was made possible because Pfizer chose to include
RCC in the initial MAA despite scientific advice that the phase II
RCC data were probably not sufficient for approval. However,
the company had a contingency plan (i.e. to withdraw RCC indica-
tion if objections were encountered). CHMP was willing to grant
conditional marketing authorisation although the legislation
was only recently put in place.
Dr. Bob Milsted congratulated Dr. Strawn on the first condi-
tional approval granted in the European Union.
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Table 1 – Objective response rates in RCC studies as assessed by core laboratory
Best overall response rate (ORR) n(%) Pivotal trial (N = 106) Supportive trial (N = 63)
Complete response (CR) 0 0
Partial response (PR) 27 (26) 16 (25)
Stable disease (P6 weeks) 65 (61) –
Progressive disease 14 (13) –
ORR (CR+PR), % (95% confidence interval) 26 (18–35) 25 (15–38)
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